⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275794 | 0.74 | — | — | |
| SCHEMBL4851582 | 0.67 | NPC1 (0.32) | — | |
| SCHEMBL5538900 | 0.64 | KIF11 (0.43) | — | |
| SCHEMBL2045954 | 0.64 | — | — | |
| SCHEMBL8085266 | 0.64 | KDM4E (0.32) | — | |
| SCHEMBL277548 | 0.63 | — | — | |
| SCHEMBL6803944 | 0.60 | — | — | |
| SCHEMBL1727698 | 0.59 | — | — | |
| SCHEMBL6905759 | 0.58 | — | — | |
| SCHEMBL220987 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116406362-A | Spiro [3.3] heptane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | claimed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | claimed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | claimed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | claimed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | claimed |
| EP-2782565-B1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | BAYER IP GMBH (DE) | 2019-11-06 | — | — | EP | claimed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | claimed |
| EP-2920163-B1 | PYRIDYLOXYAL ALKYL CARBOXAMIDES AND THEIR USE AS ENDOPARASITICIDES AND NEMATICIDE | BAYER CROPSCIENCE AG (DE) | 2018-05-02 | — | — | EP | claimed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | claimed |
| WO-2005041888-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| CN-1596114-A | Substituted 1, 4-benzodiazepines * and their use in the treatment of cancer | DIMENSIONAL PHARM INC (US) | 2005-03-16 | — | — | CN | claimed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| WO-2004064741-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | claimed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-0846686-B1 | 1-Phenyl-pyrazol derivatives and their use as parasiticidal agents | PFIZER LTD (GB) | 2002-01-09 | — | — | EP | claimed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | claimed |
| US-6069157-A | Parasiticidal compounds | PFIZER INC. (US) | 2000-05-30 | — | — | US | claimed |
| EP-0846686-A1 | 1-Phenyl-pyrazol derivatives and their use as parasiticidal agents | Pfizer Limited (GB) | 1998-06-10 | — | — | EP | claimed |